Use of short-course oral amenamevir (helicase-primase inhibitor) for the treatment of thymidine analogue-resistant herpes simplex lesions
{{output}}
Herpes simplex virus (HSV) resistance is rare, but incidence is rising. Managing resistant HSV phenotypes in individuals living with human immunodeficiency virus (HIV) poses an increasing challenge. Here, we present two (2) cases where a short course of oral a... ...
